Biophytis SA, a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional outcomes of patients suffering from age-related diseases, including respiratory failure in patients suffering from COVID-19, today announces that it has received a “Letter of Notification” from the Nasdaq Stock Market LLC (“Nasdaq”) dated November 15, 2023, indicating that the closing price on Nasdaq of its American Depositary Shares (“ADSs”) had been less than $1.00 per ADS for a period of 30 consecutive trading days, and as such no longer satisfied Nasdaq Listing Rule 5550(a)(2).